secwatch.observer — SEC 8-K summary
======================================

Issuer:     Invivyd, Inc. (IVVD)
CIK:        0001832038
Form:       8-K
Filed at:   2024-09-23T23:59:59+00:00
Accession:  0000950170-24-108624
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Invivyd provides virology data showing PEMGARDA neutralization potency stable against current SARS-CoV-2 variants
--------------------------------------------------------------------------------

- In vitro neutralization potency of PEMGARDA against KP.3.1.1 and LB.1 variants remains in-line with prior predominant variants dating to 2022.
- Structural analysis shows 19-key-amino-acid pemivibart binding site has de minimis mutational change and 99%+ stability since Omicron BA.1.
- Emerging variants XEC and LP.1 have mutations distal to binding site, not expected to meaningfully alter pemivibart activity; routine testing follows.
- Data from independent LabCorp Monogram Biosciences lab; company expects sustained neutralization based on structural biology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1832038/000095017024108624/0000950170-24-108624-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1832038/000095017024108624/ivvd-20240923.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-108624

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer